Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Cyclosporin metabolite; weak calmodulin inhibit...
Bisphosphonate.
Aminoglycoside; protein translation inhibitor.<...
NS3/4A inhibitor
Diterpene alkaloid found in Lagochilus.
5-HT1A agonist, α1-adrenergic antagonist.
Steroidal alkaloid found in Fritillaria; TRPV1 ...
Endogenous peptide hormone, involved in cell gr...
Folic acid derivative
H+/K+ ATPase inhibitor.
Macrolide lactone antibiotic.
Coumarin; VKORC1 inhibitor.
Fluoroquinolone; topoisomerase IV and bacterial...
Tetrapeptide, binds cell surface integrins.
NO donor.
Pyrimidine nucleoside (cytidine) analog; DNA ch...
Potential AhR binding agent.
S-enantiomer of citalopram; SERT inhibitor.
Fluoroquinolone, S-(-) isomer of ofloxacin; top...